Suppr
超能文献

[Is the use of placebo as control group in MS drug trials still appropriate?].

作者信息

Haghikia A, Gold R

机构信息

St. Josef-Hospital Bochum, Neurologische Klinik der Ruhr-Universität Bochum, Gudrunstr. 56, 44791, Bochum, Deutschland,

出版信息

Nervenarzt. 2015 Apr;86(4):481-2. doi: 10.1007/s00115-015-4283-z.

DOI:10.1007/s00115-015-4283-z

PMID:25787726

Abstract

摘要

相似文献

[Is the use of placebo as control group in MS drug trials still appropriate?].

Nervenarzt. 2015 Apr;86(4):481-2. doi: 10.1007/s00115-015-4283-z.

Placebo and nocebo effects in randomized controlled trials: the implications for research and practice.

J Pain Symptom Manage. 2013 Nov;46(5):722-30. doi: 10.1016/j.jpainsymman.2012.12.005. Epub 2013 Mar 22.

Placebo power.

Tech Vasc Interv Radiol. 2012 Jun;15(2):150-2. doi: 10.1053/j.tvir.2012.02.008.

What can be learned from open direct comparative trials in multiple sclerosis?

J Neurol Sci. 2009 Feb 1;277 Suppl 1:S25-8. doi: 10.1016/S0022-510X(09)70008-5.

Multiple sclerosis: Dimethyl fumarate is coming of age.

Nat Rev Neurol. 2016 Aug;12(8):436-7. doi: 10.1038/nrneurol.2016.106. Epub 2016 Jul 22.

Cost-effectiveness analyses of treatments for multiple sclerosis: are they clinically relevant?

Neurology. 2011 Jul 26;77(4):317-8. doi: 10.1212/WNL.0b013e318227066d. Epub 2011 Jul 20.

Evidence for use of glatiramer acetate in multiple sclerosis.

Lancet Neurol. 2005 Feb;4(2):74-5; discussion 76-7. doi: 10.1016/S1474-4422(05)00974-9.

Evidence for use of glatiramer acetate in multiple sclerosis.

Lancet Neurol. 2005 Feb;4(2):75-6; discussion 76-7. doi: 10.1016/S1474-4422(05)00975-0.

Transforming multiple sclerosis trials into practical reality.

Lancet Neurol. 2011 Jun;10(6):493-4. doi: 10.1016/S1474-4422(11)70100-4. Epub 2011 May 13.

Management of worsening multiple sclerosis with mitoxantrone: a review.

Clin Ther. 2006 Apr;28(4):461-74. doi: 10.1016/j.clinthera.2006.04.013.

本文引用的文献

[Pegylated interferon beta 1a. A new therapy option for treatment of relapsing-remitting multiple sclerosis].

Nervenarzt. 2015 Apr;86(4):483-90. doi: 10.1007/s00115-015-4287-8.

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Lancet Neurol. 2014 Jul;13(7):657-65. doi: 10.1016/S1474-4422(14)70068-7. Epub 2014 Apr 30.

Therapies for multiple sclerosis: translational achievements and outstanding needs.

Trends Mol Med. 2013 May;19(5):309-19. doi: 10.1016/j.molmed.2013.03.004. Epub 2013 Apr 10.

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

Lancet. 2013 Jun 22;381(9884):2167-75. doi: 10.1016/S0140-6736(12)62190-4. Epub 2013 Apr 4.

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.

Neurology. 2008 Mar 25;70(13 Pt 2):1134-40. doi: 10.1212/01.wnl.0000306410.84794.4d.

Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS.

Ann Neurol. 2001 May;49(5):677-81.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

[Is the use of placebo as control group in MS drug trials still appropriate?].

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译